CELLDEX THERP.INCO. sees a downgrade to Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of CELLDEX THERP.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date November 9, 2018, the closing price was USD 0.36 and its target price was estimated at USD 0.17.Celldex Therapeutics is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company's drug candidates, including antibodies, antibody-drug conjugates and other protein-based therapeutics are derived from a set of technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. As of Dec 31 2017, the company had seven drug candidates in clinical development including glembatumumab vedotin (also referred to as CDX-011), varlilumab (also referred to as CDX-1127), CDX-3379, CDX-014, CDX-1140, CDX-301 and CDX-1401.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.